Payment overview · 2025
General Payments
$202.30
10 reported records · 6 companies
Healthcare provider profile · identity verified
Mark David Richardson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MARSHALL, MI · NPI 1669449443
Verified facts
What the public records show
CMS Open Payments records show Mark David Richardson, M.D. received $202.30 in general payments during 2025 across 10 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.21 | 29.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.03 | 22.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.68 | 21.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.61 | 9.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.83 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.94 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.30 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.68 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.37 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 655 | 179 |
| Lisinopril | Lisinopril | 418 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 347 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 330 | 57 |
| Losartan Potassium | Losartan Potassium | 299 | 77 |
| Tamsulosin Hcl | Tamsulosin Hcl | 294 | 90 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 85 |
| Omeprazole | Omeprazole | 281 | 85 |
| Gabapentin | Gabapentin | 257 | 50 |
| Alprazolam | Alprazolam | 204 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 59 |
| Metformin Hcl | Metformin Hcl | 169 | 43 |
| Tramadol Hcl | Tramadol Hcl | 164 | 36 |
| Eliquis | Apixaban | 150 | 37 |
| Allopurinol | Allopurinol | 149 | 32 |
| Mounjaro | Tirzepatide | 130 | 18 |
| Simvastatin | Simvastatin | 123 | 36 |
| Furosemide | Furosemide | 122 | 43 |
| Prednisone | Prednisone | 119 | 60 |
| Trazodone Hcl | Trazodone Hcl | 114 | 30 |
| Famotidine | Famotidine | 108 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 29 |
| Meloxicam | Meloxicam | 97 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 14 |
| Sertraline Hcl | Sertraline Hcl | 93 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 26 |
| Celecoxib | Celecoxib | 89 | 29 |
| Pregabalin | Pregabalin | 88 | 16 |
| Potassium Chloride | Potassium Chloride | 86 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 28 |
| Bupropion Xl | Bupropion Hcl | 83 | 27 |
| Clonazepam | Clonazepam | 81 | 13 |
| Finasteride | Finasteride | 81 | 24 |
| Glimepiride | Glimepiride | 81 | 20 |
| Carvedilol | Carvedilol | 80 | 22 |
| Metformin Hcl Er | Metformin Hcl | 74 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 18 |
| Spironolactone | Spironolactone | 72 | 19 |
| Lorazepam | Lorazepam | 67 | 15 |
| Montelukast Sodium | Montelukast Sodium | 61 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | 16 |
| Ezetimibe | Ezetimibe | 59 | 18 |
| Trulicity | Dulaglutide | 59 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 16 |
| Donepezil Hcl | Donepezil Hcl | 55 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 12 |
| Warfarin Sodium | Warfarin Sodium | 51 | 12 |
| Xarelto | Rivaroxaban | 50 | 13 |
| Bumetanide | Bumetanide | 49 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 13 |
| Myrbetriq | Mirabegron | 47 | 16 |
| Chlorthalidone | Chlorthalidone | 46 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 42 | suppressed |
| Diazepam | Diazepam | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Azithromycin | Azithromycin | 39 | 34 |
| Buspirone Hcl | Buspirone Hcl | 39 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Estradiol | Estradiol | 39 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 37 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Atenolol | Atenolol | 34 | 11 |
| Lansoprazole | Lansoprazole | 34 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 33 | suppressed |
| Cephalexin | Cephalexin | 32 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 13 |
| Primidone | Primidone | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 25 | 16 |
| Jardiance | Empagliflozin | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 17 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Armour Thyroid | Thyroid,pork | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 14 |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 12 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 13 | 13 |
| Torsemide | Torsemide | 13 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Baclofen | Baclofen | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.30 · 10 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, NEXIUM, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, TRINTELLIX, UBRELVY, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error